Relay Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended June 30, 2025, none of our directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.
Departure of Directors or Certain Officers
On August 4, 2025, Brian Adams informed the company's Board of Directors that he is resigning from his position as the Company's Chief Legal Officer and Secretary, effective as of August 8, 2025. Mr. Adams' resignation is not the result of any dispute or disagreement with the company. Mr. Adams will not receive any severance payments or benefits in connection with his departure. To enable a smooth transition, Mr. Adams has agreed to providead hoc transition support to the company for no additional cash compensation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.